Compare AbbVie Inc (ABBV) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? AbbVie Inc trades at $248.43 (market cap $441.94B), while Global X NASDAQ 100 Covered Call ETF trades at $18.18. The key difference: AbbVie Inc pays a 2.77% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals.
| ABBV | QYLD | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $18.52 |
52-Week Low | $197.38 | $16.46 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
QYLD trades at $18.185, showing modest daily gains of 0.19% with a bullish technical signal from moving averages despite overbought RSI conditions. The ETF maintains its covered call strategy focus, generating high dividend yields around 12% through systematic options writing on Nasdaq-100 components. Recent dividend payments of $0.18-$0.19 per share demonstrate consistent income distribution to shareholders.
The outlook remains balanced between high income generation and growth limitations. While the 12% yield attracts income-focused investors, long-term underperformance versus the underlying index presents a key trade-off. Market sentiment is divided between yield attractiveness and capital appreciation concerns, requiring careful consideration of investment objectives and risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
